Obagi Medical shared new data at the recent ASDS Annual Meeting, highlighting the effectiveness of their Hyaluronic Acid filler for midface augmentation, as well as the positive results of their Scalp Serum. The study compared their filler to Juvéderm Voluma® XC and showed high patient satisfaction and safety. Obagi’s commitment to innovation in skincare and injectables was underscored by these findings, showcasing their leadership in the industry. The products are designed to provide natural-looking results with a focus on patient satisfaction and safety. Obagi’s Nu-Cil® BioStim™ Scalp Serum leverages their expertise in skin health to promote scalp health and hair appearance with clinically proven actives.

Read more at GlobeNewswire: Obagi Medical Shares New Clinical Data on Obagi Hyaluronic